Welcome to the UPF Digital Repository

Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection.

Show simple item record

dc.contributor.author Lerma-Chippirraz, Elisabet
dc.contributor.author Güerri Fernández, Roberto
dc.contributor.author Villar García, Judit
dc.contributor.author González Mena, Alicia
dc.contributor.author Guelar Grinberg, Ana
dc.contributor.author Montero, M.
dc.contributor.author Sorli Redó, M. Luisa
dc.contributor.author Calzado, Sonia
dc.contributor.author Horcajada Gallego, Juan Pablo
dc.contributor.author Díez Pérez, Adolfo
dc.contributor.author Knobel Freud, Hernando
dc.date.accessioned 2017-03-16T07:59:11Z
dc.date.available 2017-03-16T07:59:11Z
dc.date.issued 2016
dc.identifier.citation Lerma-Chippirraz E, Güerri-Fernández R, Villar García J, González Mena A, Guelar Grinberg A, Montero MM. Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection. AIDS Res Treat. 2016;2016:5120831
dc.identifier.issn 2090-1240
dc.identifier.uri http://hdl.handle.net/10230/28244
dc.description.abstract Hypovitaminosis D and secondary hyperparathyroidism are frequent among HIV-infected patients. As there are no data about the best supplementation therapy both in treatment and in maintenance, we conducted an observational study of 300 HIV-infected patients for whom vitamin D and parathormone (PTH) had been measured in order to validate a protocol of vitamin D supplementation in patients with HIV-infection. Patients with vitamin D deficiency (defined as 25(OH)D < 10 ng/mL), insufficiency (defined as 25(OH)D < 20 ng/mL), or hyperparathyroidism (PTH > 65 pg/mL) were supplemented with cholecalciferol 16.000IU (0.266 mg) weekly (if deficiency) or fortnightly (if insufficiency or high PTH levels). Rates of normalization of 25(OH)D (levels above 20 ng/mL) and PTH levels (<65 pg/mL) were analyzed. Multivariate analysis of factors related to normalization was carried out. With a median follow-up of 2 years, 82.1% of patients with deficiency and 83.9% of cases with insufficiency reached levels above 20 ng/mL. However, only 67.2% of individuals with hyperparathyroidism at baseline reached target levels (<65 pg/mL). Independent factors for not achieving PTH objective were tenofovir (TDF) and protease inhibitors use. In HIV-infected patients with hypovitaminosis, the protocol of cholecalciferol supplementation normalized vitamin D levels regardless of antiretroviral regimen in a high proportion of patients but it was less effective to correct hyperparathyroidism.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Hindawi
dc.rights Copyright © 2016 Elisabet Lerma-Chippirraz et al. This is an open access article distributed under https://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject.other VIH (Virus) -- Tractament
dc.subject.other Vitamines
dc.title Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection.
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1155/2016/5120831
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking